Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington.
The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates.
technical indicators:
- 100% Barchart technical buy signals
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 10 new highs and up 22.44% in the last month
- Relative Strength Index 68.80%
- Barchart computes a technical support level at 42.61
- Recently traded at 52.85 with a 50 day moving average of 38.77
Fundamental factors:
- Market Cap $1.95 billion
- Revenue expected to decrease 98.10% this year but increase again by 1,367.30% next year
- Earnings estimated to decrease by 643.30% this year and decrease again by an additional 14.10% next year
- Despite this poor projections Wall Street analysts issued 2 strong buy and 1 buy recommendation.
No comments:
Post a Comment